A Phase I Study Of Combination Neoadjuvant Hormone Therapy And Weekly OGX-011 (Clusterin Antisense Oligonucleotide) Prior To Radical Prostatectomy In Patients With Localized Prostate Cancer.

Trial Profile

A Phase I Study Of Combination Neoadjuvant Hormone Therapy And Weekly OGX-011 (Clusterin Antisense Oligonucleotide) Prior To Radical Prostatectomy In Patients With Localized Prostate Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Custirsen (Primary) ; Buserelin; Flutamide
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 12 Sep 2009 Planned end date (5 May 2004) added as reported by National Cancer Institute of Canada.
    • 11 Aug 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 10 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top